| Zacks Company Profile for Catalyst Pharmaceuticals, Inc. (CPRX : NSDQ) |
|
|
| |
| • Company Description |
| Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
Number of Employees: 181 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $21.85 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,271,713 shares |
| Shares Outstanding: 121.97 (millions) |
| Market Capitalization: $2,665.16 (millions) |
| Beta: 0.66 |
| 52 Week High: $26.58 |
| 52 Week Low: $15.34 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-10.05% |
-13.41% |
| 12 Week |
-2.98% |
-18.39% |
| Year To Date |
4.70% |
-1.95% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Richard J. Daly - Chief Executive Officer and President
Patrick J. McEnany - Chairman of the Board of Directors
Michael W. Kalb - Executive Vice President and Chief Financial Offic
Charles B. O'Keeffe - Director
David S. Tierney - Director
|
|
Peer Information
Catalyst Pharmaceuticals, Inc. (GSAC)
Catalyst Pharmaceuticals, Inc. (CASI)
Catalyst Pharmaceuticals, Inc. (ALCD.)
Catalyst Pharmaceuticals, Inc. (OMNN)
Catalyst Pharmaceuticals, Inc. (CGPI.)
Catalyst Pharmaceuticals, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 14888U101
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
|
|
Share - Related Items
Shares Outstanding: 121.97
Most Recent Split Date: (:1)
Beta: 0.66
Market Capitalization: $2,665.16 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.53 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $2.16 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 11.34% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/06/25 |
|
|
|
| |
